FUNDAMENTALS
EdgeFII/DII
MANKINDMankind Pharma
₹2,665.00+1.37%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
MANKINDNSE · EquityPharmaceuticals

Mankind Pharma

ISIN
INE634S01028
Instrument key
NSE_EQ|INE634S01028
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹2,665.00+36.00 · +1.37%
Day rangecircuit ₹2,398.50 – ₹2,931.50
2,620.20
2,669.90

as of 21/11/2026, 1:57:37 pm

Open
₹2,627.00
Day high
₹2,669.90
Day low
₹2,620.20
Prev. close
₹2,629.00
Volume
4.56 L
VWAP
₹2,646.06

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 day · 5-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX

No candles for this range

Intraday candles are empty outside market hours — pick a longer range.

Candle data0 rows of open, high, low, close and volumeShowHide

No candles in this range

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

48.54
Company
48.54
Sector
-45.02

Worse than sector by 208%

P/B

Price ÷ book value per share

6.25
Company
6.25
Sector
4.21

Worse than sector by 48%

ROA

Net income ÷ total assets

7.82%
Company
7.82%
Sector
1.19%

Better than sector by 557%

ROE

Net income ÷ shareholders' equity

12.76%
Company
12.76%
Sector
-0.4%

Better than sector by 3290%

ROCE

EBIT ÷ capital employed

14.68%
Company
14.68%
Sector
15.44%

Worse than sector by 5%

Quick Ratio

Liquid assets ÷ current liabilities

0.74
Company
0.74
Sector
4.8

Worse than sector by 85%

EV/EBITDA

Enterprise value ÷ EBITDA

26.33
Company
26.33
Sector
22.86

Worse than sector by 15%

04/Business

About the company

Sector: Pharmaceuticals

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.

Sector market cap (INR)
₹1,09,870 Cr

reported in crore

Sector market cap (USD)
$12.21B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹4,433 Cr
+8.76% vs Jun 2026
Net profit · Sep 2026
₹716 Cr
+24.74% vs Jun 2026
Operating margin
21.0%
was 18.9%
Revenue CAGR · 4p
6.8%
profit 20.1% · op 22.2%
Filed order
Revenue4,4334,0763,5573,640
Revenue growthreported8.8%14.6%-2.3%—
Operating profit929769659509
Operating profit growthreported20.8%16.7%29.5%—
Operating marginderived21.0%18.9%18.5%14.0%
Net profit716574559414
Net profit growthreported24.7%2.6%35.2%—
Net marginderived16.2%14.1%15.7%11.4%
EPS — basic₹/share, annual——46.35—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue14,27812,20710,2608,749
Other Income359537280129
Total Revenue14,63612,74410,5418,878
Total Expenses12,18610,2408,1587,219
Profit Before Tax2,3332,5162,3981,671
Tax395510457362
Profit After Tax1,9382,0071,9411,310
EPS - Basic46.3549.2847.7532.00
EPS - Diluted46.2849.1947.6832.00

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹28,080 Cr
+1.15% YoY
Total liabilities
₹11,518 Cr
Net worth
₹16,561 Cr
Liabilities ÷ assets
41.0%
lower means a lighter balance sheet
Filed order
Total assets28,08027,76011,9639,715
Total liabilities11,51813,1912,3872,092
Net worthderived16,56114,5689,5767,623
Liabilities ÷ assetsderived41.0%47.5%20.0%21.5%
Asset growthderived1.2%132.0%23.1%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets21,12520,7715,3955,388
Current Assets6,9546,9886,5684,328
Total Assets28,08027,76011,9639,715
Current Liabilities6,5075,6642,1201,863
Net Current Asset4471,3254,4482,465
Non-Current Liabilities5,0117,528268229
Equity Capital16,56114,5689,5767,623
Total Equity & Liabilities28,08027,76011,9639,715

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹3,121 Cr
+29.33% YoY
Investing
-₹196 Cr
Financing
-₹2,953 Cr
Free cash flow
₹2,925 Cr
operating + investing
Filed order
Operating activities3,1212,4132,1521,813
Operating changereported29.3%12.1%18.7%—
Investing activities-196-12,683-2,082-1,054
Investing changereported98.5%-509.3%-97.5%—
Financing activities-2,95310,2335-740
Financing changereported-128.9%194067.0%100.7%—
Net cash flowderived-28-377619
Free cash flowoperating + investing2,925-10,27071759

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax2,3332,5252,3991,671
Income before WC changes3,6093,1272,6121,970
Change in Assets-384-441-226223
Change in Liabilities489295209-56
Change in WC105-146-18167
Cash flow from Operations3,1212,4132,1521,813
Cash flow from Investing-196-12,683-2,082-1,054
Cash flow from Financing-2,95310,2335-740
Total Cash Flow-28-377619
Cash (Start of the year)404382305283
Cash (End of the year)392404382305

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
72.62%
-0.01 pts QoQ
FII
9.37%
-0.08 pts QoQ
DII (other)
4.25%
-0.27 pts QoQ
Mutual funds
11.31%
+0.44 pts QoQ
Retail & others
2.45%
-0.08 pts QoQ
Filed order
Promoters72.6%72.6%72.7%72.7%
FII9.4%9.4%10.2%11.3%
DII (other)4.3%4.5%4.1%4.0%
Mutual funds11.3%10.9%10.4%9.3%
Retail & others2.5%2.5%2.6%2.8%
Promoters — QoQ changepts, derived-0.0%-0.0%0.0%—
FII — QoQ changepts, derived-0.1%-0.8%-1.1%—
DII (other) — QoQ changepts, derived-0.3%0.4%0.1%—
Mutual funds — QoQ changepts, derived0.4%0.5%1.1%—
Retail & others — QoQ changepts, derived-0.1%-0.1%-0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

No corporate actions on record

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.